ONCURA Signs Agreement With Novation To Provide Prostate Brachytherapy Products For A New Three-Year Term

PLYMOUTH MEETING, Pa., June 14 /PRNewswire/ -- ONCURA, a global leader in the minimally invasive management of prostate cancer, and Novation, LLC, the health care contracting services company of VHA Inc. and the University Health System Consortium (UHC), announced today that ONCURA has been awarded a three- year contract to provide VHA Inc. and UHC members with a complete portfolio of prostate brachytherapy products. The three-year agreement was effective from June 1, 2006 and offers ONCURA's Iodine-125 and Palladium-103 products.